Halozyme Therapeutics announced that new data from the global phase III FeDeriCa study conducted by Genentech/Roche will be presented at...

Kite, a Gilead Company announced that it has submitted a Biologics License Application (BLA) to the FDA for the investigational...

Seattle Genetics, Inc. announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer...

Amgen and UCB announced that the European Commission has granted marketing authorization for Evenity (romosozumab) for the treatment of severe...

Daiichi Sankyo presented positive detailed data from the global pivotal phase II single-arm DESTINY-Breast01 trial of DS-8201 ([fam-] trastuzumab deruxtecan),...

Data from the follow-up (median of 36.4 months) of the Phase III MAIA study (Abstract #1875) was presented at ASH...

Genentech, a member of the Roche Group announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA)...

Merck and ArQule, Inc.announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will...

Kite, a Gilead Company announced primary results from ZUMA-2 , a global, multicenter, single-arm, open-label Phase II study of KTE...

LEO Pharma announced that CAT 354 (tralokinumab) met all primary and secondary endpoints in its three pivotal Phase III studies...